FDA Warns Consumers About Possible Chantix Cardiovascular Risks

Posted on

The Food and Drug Administration is warning consumers about the results of a study which suggests that users of Chantix might be at risk of suffering some sort of adverse cardiovascular event.  Chantix, which is provided to individuals who seek to cut their smoking habit, was compared to placebo intake during a series of clinical trials.  By analyzing these trials, it was noted that things like nonfatal strokes and heart attacks, as well as fatal cardiovascular incidents, were more prevalent in those persons who had been provided Chantix as opposed to the placebo.  However, the FDA states that the heightened risk was relatively slight and thus could be attributable to chance.  Doctors are being asked to consider the risks before prescribing the medication.

Click here to learn more about the possible risks.